| Date | Title | Description |
| 28.08.2026 | China’s InnoCare Pharma Turns a Profit in First Half on Surging Overseas Licensing Revenue | (Yicai) Aug. 28 -- Chinese drugmaker InnoCare Pharma swung into the black in the first half of the year, buoyed by rapid revenue growth from overseas licensing deals.
InnoCare had a net profit of CNY239.7 million (USD35.7 million) in the si... |
| 26.03.2026 | Keymed Biosciences Announces 2025 Annual Results and Business Updates | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.
Revenue Leaps... |
| 24.03.2026 | Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологию | По условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336... |
| 05.03.2026 | Prolium Bioscience Raises $50M in Series A Funding | Prolium Bioscience, a NYC-based clinical stage biotechnology company, raised $50M in Series A funding.
The round was led by RTW Investments (RTW).
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO... |
| 27.08.2025 | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially, the company achie... |
| 14.05.2025 | China's InnoCare Turns First Profit in First Quarter | (Yicai) May 14 -- InnoCare Pharma posted a profit in the first quarter of this year for the first time, mainly thanks to a surge in sales of the Chinese firm's core leukemia drug.
Net profit was CNY18 million (USD2.5 million) in the three m... |
| 25.04.2025 | Keymed Biosciences: A New Dawn in Cancer Treatment with CM518D1 | In the world of oncology, hope often feels like a flickering candle in a storm. Yet, Keymed Biosciences Inc. has just lit a brighter flame. On April 25, 2025, the company announced a significant milestone: the approval of its Investigationa... |
| 25.04.2025 | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Inves... |
| 25.04.2025 | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received In... |
| 23.12.2024 | Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis | CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (th... |
| 13.09.2024 | Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults | CHENGDU, China, Sept. 13, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the new drug application for Stapokibart... |
| 29.08.2024 | Harbour BioMed and Keymed Biosciences: Navigating the Biopharmaceutical Landscape in 2024 | In the ever-evolving world of biopharmaceuticals, two companies stand out: Harbour BioMed and Keymed Biosciences. Both are charting ambitious paths through the complex terrain of drug development, showcasing resilience and innovation. Their... |
| 27.08.2024 | Keymed Biosciences Announces Interim Results for First Half of 2024 | CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update.
Rapid development of our pipeline products
Stapokibart (CM31... |
| 03.06.2024 | Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis | CHENGDU, China, June 3, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic derm... |
| 27.03.2024 | Keymed Biosciences Announces 2023 Annual Results and Business Updates | Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review.
Advanced a Phase III clinical study of Stapokibart for... |
| 15.05.2023 | Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis | SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 23.02.2023 | Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901 | CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZen... |
| 18.01.2023 | Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM | CHENGDU, China, Jan. 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug ... |
| 22.09.2022 | China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer | CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Desi... |
| 10.06.2022 | Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 | CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the tre... |
| 20.04.2022 | FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies | CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gast... |
| 12.04.2022 | CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States | CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal juncti... |
| 18.01.2022 | InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355 | BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient in China has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody deve... |
| 17.09.2021 | InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355 | BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture... |
| - | Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis | CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic derm... |